Table 1.

In vitro activity of GNS561 and HCQ in human cancer cell lines (left, IC₅₀ ± SD, µM) and in vitro activity of GNS561 and sorafenib in primary HCC patient-derived cells (right, IC₅₀, µM)

		Mean IC50 ± SD (µM)			IC50 (μM)
Cancer type	Cell lines	GNS561	HCQ	Primary HCC patient-derived cells	GNS561	sorafenib
Colon Carcinoma	HCT-116	1.22 ± 0.15	14.41 ± 1.5	LI0050	3.54	9.12
	HT-29	1.35 ± 0.04	24.18 ± 5.14	LI0574	2.41	8.65
Renal Cell Carcinoma	786-O	1.72 ± 0.17	21.65 ± 3.15	LI0612	6.93	17.94
	CAKI-1	1.10 ± 0.19	17.69 ± 1.29	LI0752	0.49	6.34
Ovarian Cancer	NIH:OVCAR3	7.27 ± 1.71	98.01 ± 12.75	LI0801	2.07	5.7
Melanoma	A375	1.2 ± 0.13	12.27 ± 2.8	LI1005	3.16	14.49
	SK-MEL-28	1.81 ± 0.5	22.78 ± 2.65	LI1098	6.95	10.85
Breast Cancer	MDA-MB-231	2.17 ± 0.14	14.13 ± 3.06	LI1646	1.44	10.33
Prostate Cancer	DU-145	1.09 ± 0.18	45.74 ± 0.55	Mean	3.37 ± 2.40	10.43 ± 4.09
	PC-3	2.56 ± 0.23	43.43 ± 6.04
Lung Cancer	A549	1.69 ± 0.34	14.33 ± 1.59
	NCI-H358	2.54 ± 0.34	54.07 ± 14.19
HCC	HepG2	0.47 ± 0.15	11.55 ± 1.52
	Huh7	0.88 ± 0.31	13.62 ± 0.71
Glioblastoma	LN-229	0.60 ± 0.24	10.87 ± 1.23
	LN-18	0.22 ± 0.06	5.27 ± 0.74
Acute Myeloid Leukemia	KG-1	5.86 ± 1.64	43.92 ± 2.76
	Mean	1.99 ± 1.86	27.52 ± 23.28